Valuation: Edesa Biotech, Inc.

Market Cap 64.11M 56.1M 51.7M 47.92M 90.98M 6.08B 92.44M 620M 241M 3B 241M 235M 10.38B P/E 2026 *
-4.34x
P/E 2027 * -3.59x
Enterprise Value 64.11M 56.1M 51.7M 47.92M 90.98M 6.08B 92.44M 620M 241M 3B 241M 235M 10.38B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
79.78%
Yield 2026 *
-
Yield 2027 * -
1 day+1.25%
1 week-10.21%
Current month-10.21%
1 month+35.94%
3 months+20.66%
6 months+374.03%
Current year+414.08%
1 week 7.01
Extreme 7.01
8
1 month 4.56
Extreme 4.56
8.89
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 31/07/2015
Director of Finance/CFO 57 30/04/2025
President 48 06/06/2019
Director TitleAgeSince
Chairman 50 06/06/2019
Director/Board Member 55 06/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap.
07-01Free

Founder

3,378 0.0380%
06-15Free

Founder

153,550 1.7268%
06-15Sell

Founder

153,530 1.7266%
Change 5-day change 1-year change 3-year change Capi.($)
+1.25%-10.21%+254.37%+24.15% 64.11M
-0.10%+3.41%+73.88%+130.87% 57.73B
-3.80%-6.24%+67.04%+86.36% 54.69B
+0.38%+1.33%-14.32%-11.76% 23.75B
+1.17%+5.83%+16.39%+468.18% 24.18B
-2.70%+4.25%+40.38%-3.72% 19.82B
+3.78%+5.65%+44.99%-26.23% 17.14B
+3.46%+17.72%+206.66%+364.07% 16.75B
-1.81%+18.00%+41.99% - 15.57B
+2.79%+4.91%+29.26%+195.60% 13.96B
Average +0.44%+4.40%+76.06%+136.39% 24.36B
Weighted average by Cap. -0.39%+3.33%+57.87%+138.66%

Financials

2026 *2027 *
Net sales - -
Net income -14.54M -12.72M -11.72M -10.87M -20.63M -1.38B -20.96M -141M -54.67M -681M -54.57M -53.39M -2.35B -26.51M -23.2M -21.38M -19.82M -37.62M -2.52B -38.23M -256M -99.71M -1.24B -99.54M -97.38M -4.29B
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
17
Date Price Change Volume
07/07/26 US$7.300 +1.25% 60,049
06/07/26 US$7.210 -3.87% 65,719
02/07/26 US$7.500 -3.23% 68,266
01/07/26 US$7.750 -4.67% 46,915
30/06/26 US$8.130 +6.00% 192,344
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.210USD
Average target price
16.33USD
Spread / Average Target
+126.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock